StockWatch
·
Biotechnology: Pharmaceutical Preparations
AGM/EGMNov 20, 2026, 06:07 AM

Alterity Therapeutics Secures FDA Alignment for ATH434 Phase 3 Trial

AI Summary

Alterity Therapeutics Limited filed a Form 6-K, incorporating by reference the Chairman's Address to the 2026 AGM and CEO Presentation. The Chairman, Julian Babarczy, highlighted significant progress in the development of ATH434 for Multiple System Atrophy (MSA). Key achievements include alignment with the FDA on the design and potential registrational pathway for a Phase 3 trial, strengthening the company's development program and providing a clear framework for future steps. The company also advanced its scientific evidence base, completed manufacturing of a registration batch of ATH434, and secured a new US composition of matter patent extending protection to 2045. The company is now focused on securing funding for the Phase 3 program, with approximately A$41.3 million in cash as of September.

Key Highlights

  • Alterity Therapeutics achieved alignment with the FDA on the design and potential registrational pathway for a Phase 3 trial of ATH434 in MSA.
  • A new US composition of matter patent for ATH434 has been secured, extending protection to 2045.
  • The company successfully produced its first registration batch of ATH434.
  • Alterity Therapeutics held its 2026 Annual General Meeting, with the Chairman's Address and CEO Presentation incorporated by reference.
  • The company ended September with A$41.3 million in cash, with a focus on securing funding for the upcoming Phase 3 program.